Related Blog Posts from the Wikinvest Wire

Regeneron Pharmaceuticals (REGN)   Subscribe to Regeneron Pharmaceuticals (REGN) content from the Wikinvest Wire
 » Back to Regeneron Pharm… (NASDAQ:REGN) Stock Page


9/16/14Market Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – EYLEA® (aflibercept) Injection Re... (Jutia Group)

[PR Newswire] - TARRYTOWN, N.Y., Sept. 16, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted EYLEA® (aflibercept) Injection Breakthrough Therapy designation for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). The designation is based on positive results in [...]

8/19/14Company Update (NASDAQ:REGN): Regeneron Announces Upcoming 2014 Investor Conference Presentations (Jutia Group)

[PR Newswire] - TARRYTOWN, N.Y., Aug. 19, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast management presentations at the following investor conferences: Sanofi and Regeneron will host ... Read more on this. Regeneron Pharmaceuticals, Inc. (REGN), with a current market cap of $34.91B, opened this morning at $349.94.   [...]

8/4/13(SNY) Sanofi and Regeneron Pharmaceuticals Dupilumab Data Published (Stock Blog Hub)

Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) recently announced that positive data from a phase IIa study evaluating dupilumab (REGN668/SAR231893) for moderate-to-severe allergic asthma was published in the New England Journal of Medicine. The study (n = 104) evaluated the efficacy and safety of dupilumab in patients suffering from moderate-to-severe persistent asthma whose disease was [...]

4/18/13(REGN) Regeneron Pharmaceuticals Rated Neutral Again (Stock Blog Hub)

We recently maintained our Neutral recommendation on biopharmaceutical company, Regeneron Pharmaceuticals (REGN). Our target price is $195.00 per share. Why the Reiteration? Regeneron reported higher-than-expected earnings in the fourth quarter of 2012, on the back of strong sales of its eye-drug Eylea. The drug has performed well since its US launch in late 2011 for treating patients [...]

1/30/13Regeneron (Nasdaq: REGN): Have You Missed the Boat? (Investment U)

In case you didn’t know, three weeks ago was the J.P. Morgan Healthcare Conference in San Francisco. It’s a big deal with a who’s who of bigwigs in the industry... >> Regeneron (Nasdaq: REGN): Have You Missed the Boat?

12/3/12Biotech of the Year (Wealth Daily)

Regeneron Pharmaceuticals (NASDAQ: REGN) is recognized in the eighth-annual Biotechnology Company of the Year Awards...

8/20/12(REGN) Regeneron Pharmaceuticals Gets FDA Complete Response Letter (Stock Blog Hub)

Regeneron Pharmaceuticals Inc. (REGN) recently suffered a setback in its efforts to expand the label of its drug Arcalyst. The US Food and Drug Administration (FDA) declined to approve Arcalyst for preventing gout flares in patients initiating uric acid-lowering therapy on the basis of the submitted data. The US regulatory body issued a complete response letter [...]

11/22/11Regeneron Receives FDA Approval; Begins to Eye Bright Future (Benzinga)

Regeneron Pharmaceuticals (NASDAQ: REGN) announced that it had received approval for Eylea, a treatment for wet macular degeneration. The disease can cause blindness in patients and occurs when fluid leaks from blood vessels and affects the position of the macula in the eye, which initially distorts vision. The drug hopes to compete with the generic Avastin, which has historically been used off label, but has shown to have serious side effects if not packaged properly. Eylea faces tough...

10/7/11CMTL, REGN, WPRT, SGEN Among Charts to Watch (Wall Street Sector Selector)

The stock market has had three consecutive up days this week. Friday may possibly be a consolidation day. We’ll just have to see what occurs. For now, we’re going to continue to look at stocks that are looking very well. Comtech ...

9/3/11Regeneron Pharmaceuticals Shares Jumped: What You Need to Know (Penny Stock DD)

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of drugmaker Regeneron Pharmaceuticals (Nasdaq: REGN  ) popped 10% in intraday trading Friday after The New York Times reported that Roche's age-related [...]

7/14/11(REGN) Regeneron Pharmaceuticals Gets Mixed Data for REGN88 (Stock Blog Hub)

Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi Aventis (SNY) recently announced data from two mid-stage studies of their pipeline candidate sarilumab (REGN88/SAR153191). While one study (MOBILITY) evaluated patients with rheumatoid arthritis (RA) the other (ALIGN) evaluated ankylosing spondylitis (AS) patients. Sarilumab is an antibody targeting the interleukin-6 receptor (IL-6R). The data from the RA trial [...]

6/29/11(REGN) Bayer Seeks Eylea Approval in Japan (Stock Blog Hub)

Germany’s Bayer (BAYRY) recently submitted an application to the Japanese Ministry of Health, Labor and Welfare (MHLW) seeking approval to market its eye treatment VEGF (vascular endothelial growth factor) trap-eye (proposed trade name: Eylea) in the country. The clearance is being sought to market the drug for treating patients suffering from the neovascular form of age-related [...]

6/21/11(REGN) Regeneron Pharmaceuticals Wins Unanious FDA Panel Approval (Stock Blog Hub)

Recently, the Dermatologic and Ophthalmic Advisory Committee of the US Food and Drug Administration (FDA) issued a positive opinion and unanimously recommended the US approval of Regeneron Pharmaceuticals Inc.’s (REGN) eye treatment VEGF (vascular endothelial growth factor) trap-eye (proposed trade name: Eylea). The panel recommended the clearance of the candidate in the US for treating patients [...]

5/6/11Baupost Going Global With London Office (REGN, THRX, ALR, CSE, VSAT) (

Seth Klarman's Baupost Group, which has $24 billion in assets under management, is opening its first overseas office later this year to take advantage of a spate of distressed debt sales caused by Europe's sovereign debt crisis, according to Bloomberg News, citing sources familiar with the matter. The new office will be located in London. Jim [...]

4/28/11Out REGN. Worst Trade For Me In a Long While (Robert Weinstein Trading Blog)

I just closed out $REGN for a painful hit. I used the William B7 signal for entry. Interestingly enough I started out really slow too because I didn’t want to get to big. I had no idea it was going to rip up over $10 higher. Had I used the improved William B9 signal I [...]

2/14/11Losers at NASDAQ Pharmaceutical Sector: (REGN, AVNR, VICL, OPTR, MNKD) (Penny Stock DD)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) witnessed the correction of 3.23% to close at $35.31 with overall traded volume of 1.03 million shares in the last trading day. Its outstanding shares stood at 82.29 million. Its total market capitalization arrived at $2.91 billion. AVANIR Pharmaceuticals (NASDAQ:AVNR) dropped by 4.53% and closed at $3.79 whereas total traded volume [...]

11/7/10(REGN) Regeneron Pharmaceuticals Quarterly Loss Wider than Expected (Stock Blog Hub)

Regeneron Pharmaceuticals Inc.'s (REGN) third quarter 2010 net loss of 41 cents per share was wider than the Zacks Consensus Estimate of a net loss of 34 cents. The company suffered a loss of 1 cent per share in the year-ago quarter. The wider loss was attributable to lower revenues and higher expenses incurred in [...]

11/2/10Calls Purchased on Regeneron Pharmaceuticals (REGN) (Benzinga)

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) are higher on the session by 3.27%, currently trading at $26.85. The stock has been moving largely higher over the past four months after bouncing off of the $22.00 level and rallying above the 50-day and 200-day moving averages. Options traders are buying calls on the name today. A short while ago the December $30.00 call was purchased 1,000 times, on the offer, on open interest of 1,677 contracts. Overall call volume is now...

10/13/10Regeneron Announces Closing of Underwritten Offering of Common Stock; Raises $175.1M (Benzinga)

Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today the completion of its previously announced underwritten public offering of 5,500,000 shares of Common Stock, as well as 825,000 additional shares of its Common Stock pursuant to the full exercise of the over-allotment option granted to the underwriter. The total proceeds of the offering (before estimated offering expenses) were approximately $175.1 million. Citi acted as the sole book-running manager for the offering. The...

10/8/10Regeneron Increases Size of Public Offering of Common Stock (Benzinga)

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has increased the size of its previously announced underwritten public offering of Common Stock from 4,500,000 shares to 5,500,000 shares and agreed to an indicative price of $28.00 per share for the offering. Citi is serving as sole book-running manager for the offering. The offering is expected to close on October 13, 2010, subject to customary closing conditions. In addition, Regeneron has granted Citi a 30-day option...

10/6/10Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares (Benzinga)

Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it intends, subject to market conditions, to offer 4,500,000 shares of its common stock pursuant to an underwriting agreement with Citi acting as the sole bookrunner. The Company expects to use the net proceeds from the sale of the shares for general corporate purposes. Closing of the offering is expected to occur on or about October 11, 2010, subject to customary closing conditions. In addition, the Company intends to...

9/22/10Buy REGN Ahead Of VEGF Trap-Eye Data In December (Benzinga)

PiperJaffray says it is a buyer of Regeneron Pharmaceuticals (NASDAQ: REGN) ahead of pivotal VEGF Trap-Eye data in Age-related Macular Degeneration (AMD) in December. If approved, we believe VEGF Trap-Eye could be a game changer for Regeneron pushing the company to profitability in 2012. Regeneron retains U.S. rights where there are >200,000 new cases of AMD each year. PiperJaffray conservatively forecasts sales of $710 million by 2015 with only 25% penetration. If VEGF Trap-Eye proves...

8/1/10(REGN) Regeneron Pharmaceuticals’ Quarterly Loss Narrower than Expected (Stock Blog Hub)

Regeneron Pharmaceuticals Inc.’s (REGN) second-quarter 2010 net loss of $25.5 million, or 31 cents per share, was narrower than the Zacks Consensus Estimate of a net loss of 38 cents. The company suffered a loss of $14.9 million, or 19 cents per share in the year-ago quarter. The wider year-over-year loss in the reported quarter [...]

5/5/10(REGN) Regeneron Pharmaceuticals Reports Narrower-Than-Forecasted Loss (Stock Blog Hub)

Regeneron Pharmaceuticals Inc.’s (REGN) first-quarter loss of $30.5 million, or 38 cents per share, was narrower than the Zacks Consensus Estimate of a loss of 49 cents. The company suffered a loss of $15.4 million, or 19 cents per share in the year-ago quarter. This was due to higher research and development expenses although revenues [...]

5/4/10(REGN) Regeneron Pharmaceutical’s First Quarter Earnings Loss Narrower (Stock Blog Hub)

Regeneron Pharmaceuticals Inc.’s (REGN) first-quarter loss of $30.5 million, or 38 cents per share, was narrower than the Zacks Consensus Estimate of a loss of 49 cents. The company suffered a loss of $15.4 million, or 19 cents per share in the year-ago quarter. This was due to higher research and development expenses although revenues [...]

12/10/09(REGN) Regeneron Pharmaceuticals to Expand Research Positions (Stock Blog Hub)

Regeneron Pharmaceuticals Inc. (REGN) announced recently that is investing $40 million, which will result in the creation of up to 100 jobs in East Greenbush facility in Rensselaer County, coupled with another 300 jobs at its Westchester County facility, both in New York. The new positions will be created primarily for research. Regeneron increased its presence [...]

11/25/09(SNY) Sanofi-Aventis Expands Regeneron Pharmaceuticals Agreement (Stock Blog Hub)

Sanofi-Aventis (SNY) recently extended and expanded its antibody collaboration with biopharmaceutical company, Regeneron Pharmaceuticals, Inc. (REGN). The companies had initially entered into a collaboration agreement in 2007, which was scheduled to expire in 2012. Under the extended agreement, Sanofi will increase its annual funding commitment by $60 million to $160 million from 2010. Moreover, the agreement [...]

9/24/09(REGN) Regeneron Pharmaceuticals Enrolls for Studies (Stock Blog Hub)

Last week, Regeneron Pharmaceuticals, Inc. (REGN) announced the completion of enrollment in two late stage studies of its VEGF (vascular endothelial growth factor) trap-eye treatment for age-related macular degeneration (wet AMD), a leading cause of blindness in adults. Each of the randomized, double-masked trials has enrolled more than the target of 1,200 patients. The company is [...]

9/14/09(SNY) Sanofi-Aventis and Regeneron Pharmaceuticals Suffer Late-stage Pipeline Setback (Stock Blog Hub)

On Friday, Sanofi-Aventis (SNY) and collaboration partner, Regeneron Pharmaceuticals (REGN) suffered a pipeline setback with the companies halting development of their late-stage pipeline candidate, aflibercept, for the treatment of pancreatic cancer. Aflibercept, an anti-angiogenesis agent being developed for a variety of tumor types, was in a phase III study, which was evaluating the efficacy of the [...]

Your blog posts can appear here by joining the Wikinvest Wire
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki